COMPANY Overview

Established in September 2024, the company inherits the technological essence of JN MEDSYS and is dedicated to the in-depth expansion of digital PCR technology in the Chinese market. Its core business focuses on precision medicine and life science diagnostics. Built upon internationally leading technology and leveraging the research strengths of the National University of Singapore Guangzhou Innovation Institute, it aims to become a benchmark enterprise in China's digital PCR field.

Key Highlights

1) Strategic Positioning:

As the core vehicle for JN MEDSYS's strategic expansion in China, the company shoulders the vital mission of localizing cutting-edge digital PCR technology, building a bridge for precision medicine collaboration between China and Singapore.

2) Outstanding Technical Barriers: 

Through exclusive patent licensing agreements (Patent Nos.: 2016800381547, 2013800616604), the company holds sole rights to core digital PCR patents, establishing a technological moat covering critical processes such as sample processing and chip partitioning.

3) Comprehensive R&D System: 

Leveraging JN MEDSYS's elite team (40% R&D personnel) and the industry-academia-research collaboration platform at the National University of Singapore Guangzhou Innovation Institute, we have established an innovation loop of “international technology introduction + local R&D transformation,” ensuring efficient technology conversion.

4) Quality System Aligned with International Standards: 

Although in the technology transfer phase, the company has fully implemented its parent company's ISO 13485:2016 quality management system. The entire process from R&D to production adheres to international medical standards, laying a solid foundation for future product certification.

5)    Unique Innovation Model: 

Adopting a differentiated strategy of “exclusive patent licensing + technology localization,” the company conducts applied research tailored to China's market needs, forming a cost-advantaged technology transfer pathway.

6) Clear Development Path: 

Short-term focus on R&D innovation and technology transfer; mid-term goal of achieving domestic production for core products; long-term vision to establish a precision testing technology service center covering South China. Ultimately forming a dual-empowerment model: “Overseas technology localized for China – Local products internationalized.”

Team Structure and Members

Founder and CEO: Dr. Johnson NG, Ph.D. in Bioengineering from the National University of Singapore (NUS), Adjunct Professor at NUS, and a pioneer in digital PCR. He has led the team to achieve significant accomplishments in the R&D and application of digital PCR technology.

Core Team: Core team members from JN MEDSYS PTE. LTD. in Singapore, covering R&D, manufacturing, commercial, and administrative domains. Approximately 40% of team members are R&D personnel, with PhD holders accounting for about 15%. Team members possess over 10 years of experience in microfluidics, optics, and biomedical engineering.

Full Product/Service Line Description

Core Product: Clarity Plus™ Digital PCR System—an advanced genetic testing platform integrating high multiplexing, high resolution, and high throughput.

Complementary Kits: Includes EGFR T790M Mutation Kit, Epstein-Barr Virus Kit, Hepatitis B Virus Kit, etc., catering to diverse customer needs.

Technical Specifications:

Clarity Plus™ Digital PCR System:

1) Supports 6 detection channels.

2) Samples subdivided into 40,000 to 45,000 compartments.

3) Processes 96 reactions per run, generating millions of data points.

Application Cases:

Liquid Biopsy: For early cancer screening and monitoring.

Non-Invasive Prenatal Testing (NIPT): For non-invasive detection of fetal genetic disorders.

Pathogen Detection & Viral Load Quantification: For infectious disease diagnosis and treatment monitoring.

Gene Expression Analysis: For gene function research in scientific fields.

Authorized Patents:

Patent No.: 2016800381547, Patent Title: Method for Evaporating Liquid in a Microcapillary.

Patent No.: 2013800616604, Patent Title: Improved Device and Method for Sample Separation.

Other incubated enterprises